Range Financial Group LLC Acquires New Shares in Bausch Health Companies Inc. (NYSE:BHC)

Range Financial Group LLC bought a new position in shares of Bausch Health Companies Inc. (NYSE:BHC - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 124,534 shares of the company's stock, valued at approximately $1,004,000.

Several other institutional investors have also recently made changes to their positions in BHC. CIBC Asset Management Inc increased its position in Bausch Health Companies by 0.3% in the 3rd quarter. CIBC Asset Management Inc now owns 374,729 shares of the company's stock valued at $3,060,000 after buying an additional 1,082 shares in the last quarter. Northwest & Ethical Investments L.P. raised its position in shares of Bausch Health Companies by 13.0% during the third quarter. Northwest & Ethical Investments L.P. now owns 32,384 shares of the company's stock worth $264,000 after purchasing an additional 3,734 shares during the period. The Manufacturers Life Insurance Company lifted its holdings in shares of Bausch Health Companies by 2.0% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 246,808 shares of the company's stock worth $1,719,000 after purchasing an additional 4,944 shares in the last quarter. Headlands Technologies LLC acquired a new stake in Bausch Health Companies in the 2nd quarter valued at $35,000. Finally, Creative Planning raised its holdings in Bausch Health Companies by 16.9% during the third quarter. Creative Planning now owns 55,351 shares of the company's stock worth $452,000 after buying an additional 7,995 shares during the last quarter. Institutional investors and hedge funds own 78.65% of the company's stock.

Wall Street Analysts Forecast Growth

BHC has been the subject of several recent research reports. Evercore ISI raised shares of Bausch Health Companies to a "hold" rating in a research report on Tuesday, October 15th. StockNews.com raised Bausch Health Companies from a "hold" rating to a "buy" rating in a research report on Friday, October 25th. Finally, Royal Bank of Canada increased their price target on Bausch Health Companies from $10.00 to $11.00 and gave the company a "sector perform" rating in a research report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, Bausch Health Companies currently has a consensus rating of "Hold" and an average price target of $7.75.

Bausch Health Companies Stock Up 0.5 %

BHC stock traded up $0.04 during midday trading on Tuesday, hitting $7.84. The company's stock had a trading volume of 816,999 shares, compared to its average volume of 940,425. Bausch Health Companies Inc. has a 1 year low of $3.96 and a 1 year high of $11.46. The stock has a market cap of $2.84 billion, a price-to-earnings ratio of -16.33 and a beta of 0.69. The stock's 50-day moving average price is $8.22 and its 200 day moving average price is $7.41.

Bausch Health Companies (NYSE:BHC - Get Free Report) last posted its quarterly earnings data on Wednesday, October 30th. The company reported $1.12 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.02 by $0.10. Bausch Health Companies had a negative net margin of 1.88% and a negative return on equity of 755.86%. The business had revenue of $2.51 billion during the quarter, compared to the consensus estimate of $2.42 billion. During the same quarter last year, the company posted $1.03 earnings per share. The firm's quarterly revenue was up 12.2% compared to the same quarter last year. As a group, equities analysts forecast that Bausch Health Companies Inc. will post 3.74 earnings per share for the current fiscal year.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.